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Background: Despite using renin–angiotensin system (RAS) blockades, some of
the patients with immunoglobulin A (IgA) nephropathy often had persistent
proteinuria of more than 500 mg/d. They need to be managed further by
alternative methods to halt the progression of the disease; these methods could
also be applied safely over a long period of time. In this context, sulodexide has
been studied for the management of diabetic nephropathy.
Methods: A retrospective review was carried out involving 20 patients with IgA
nephropathy who had been taking sulodexide (50 mg daily) as an add-on therapy
together with an optimal dose of RAS blockades during 2008–2009. We evaluated
the proteinuria reduction rates and renal function changes.
Results: During 11.1772.7 months of follow-up duration, urinary protein-to-
creatinine ratio (UPCR) decreased for 1.5770.6 to 1.1770.7 g/g (P¼0.032).
Twenty-ﬁve percent of the patients showed a greater than 50% reduction of UPCR,
and 40% had a UPCR of less than 1.0 g/g at their ﬁnal observations. The analysis of
the factors contributing to the effect found that a higher pretreatment UPCR
showed a signiﬁcant correlation with the UPCR decrease (r¼0.45, P¼0.047).
Neither the adverse effects nor the renal function impairments were documented
during the management.
Conclusion: Low-dose sulodexide has an additional modest antiproteinuric effect
on IgA nephropathy undergoing RAS blockade therapy.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Immunoglobulin A (IgA) nephropathy is one of the most
common primary glomerulonephritides, progressing to end-rean Society of Nephrology. P
ses/by-nc-nd/4.0/).
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.stage renal disease (ESRD) in about a third of its patients over
a period of 20–25 years after diagnosis [1,2]. There are many
factors related to disease progression and development, such as
renal function at diagnosis, proteinuria, hypertension, micro-
scopic hematuria, glomerulosclerosis, interstitial ﬁbrosis, and so
forth [3–5]. Of these factors, proteinuria has been regarded as not
only a reﬂecting, but also a causative factor for renal damage [6].
A dominant therapeutic approach to IgA nephropathy is the
inhibition of the renin–angiotensin system (RAS), which can be
achieved using RAS blockades such as angiotensin-convertingublished by Elsevier. This is an open access article under the CC BY-NC-
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(ARB) [5,7]. However, the efﬁcacy of RAS blockades have been
found to be insufﬁcient in overt proteinuric IgA nephropathy;
therefore, immunosuppressive approaches, including glucocorti-
coids and/or cytotoxic agents, have been adopted [7,8]. Although
immunosuppressive regimens have shown sufﬁcient efﬁcacies in
some patients with IgA nephropathy, their adverse effects could
be problematic [9]. Therefore, we need to ﬁnd a safe and long-
term method for reducing renal damage.
Sulodexide is an oral formulation of a highly puriﬁed mixture
of glycosaminoglycans (GAGs). It is composed of 80% fast-
moving heparin sulfate and 20% dermatan sulfate, and is the
most extensively investigated GAG mixture for diabetic patients
[10,11]. It bears a strong chemical similarity to heparin, but does
not show anticoagulant properties when given orally. Sulodex-
ide has emerged as a potential treatment for diabetic nephro-
pathy. Multiple studies have demonstrated reductions in
urinary protein excretion with GAG therapy [12,13]. However,
only a few studies demonstrate the effects of sulodexide on the
management of primary glomerular diseases.
We conducted this research to investigate the antiprotei-
nuric effect of sulodexide in patients with IgA nephropathy
showing persistent proteinuria, in spite of optimal manage-
ment with RAS blockades.Table 1. Baseline characteristics
Variables n¼20
Age (y) 38.7712.7
Sex (male/female) 11/9
Time from biopsy to recruitment (y) 3.172.3
Systolic blood pressure (mmHg) 119.178.8
Diastolic blood pressure (mmHg) 74.977.1
UPCR (g/g) 1.570.6
eGFR (mL/min/1.73 m2) 70.4718.7
Duration of sulodexide therapy (mo) 11.172.7
Duration of RAS blockade therapy (y) 2.971.9
Previously-taken RAS blockades (%)
ACEi 14 (70%)
ARB 8 (40%)
ACEiþARB 2 (10%)
ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin II
receptor blockers; eGFR, estimated glomeruloﬁltration rate; RAS,
renin–angiotensin system; UPCR, urinary protein-to-creatinine ratio.Methods
Study participants
Retrospective analyses were performed in all patients with
IgA nephropathy who were on RAS blockades and sulodexide
between September 2008 and May 2009. We selected those
patients who were over 18 years old, had received RAS block-
ades, had stable blood pressure levels of less than 130/80 mmHg
for at least last 6 months, and showed persistent proteinuria
[urinary protein-to-creatinine ratio (UPCR) 40.5 g/g]. The
patients who received immunosuppressants in the last 1 year
or had systemic lupus erythematosus, chronic liver diseases,
malignancies, or inﬂammatory bowel diseases were excluded.
Data collection
We reviewed the records of the patients to collect data on
accompanying medications, comorbidities, changes of blood
pressure, and dose and duration of sulodexide administration.
Laboratory data included serum creatinine, serum albumin,
serum total cholesterol, and urinary protein levels, by checking
the UPCR on every visit to the outpatient department. Glomer-
ular ﬁltration rates (GFRs) of the participants were calculated by
the Modiﬁcation of Diet in Renal Disease Study equation.
Pathologic ﬁndings regarding IgA nephropathy of the patients
were rated into ﬁve grades, according to the WHO classiﬁcation
proposed by Churg and Sobin [14]. Speciﬁcally, we added the
data regarding the states of the foot process effacements (FPE)
on electron microscopy by grading them into three levels: mild
(o30%), moderate (30–70%), and severe (470%) [15].
Outcomes
The change in UPCR between the initiation of sulodexide
administration and the last laboratory report from the survey
was calculated to determine whether the treatment offered areasonable reduction of proteinuria. Factors related to the
antiproteinuric effect of sulodexide were analyzed as well.
Statistical analysis
The SPSS (SPSS version 15.0; SPSS Inc., Chicago, IL, USA)
package was used for statistical analysis. The efﬁcacy of sulodex-
ide in diminishing proteinuria during treatment was analyzed
using the Wilcoxon signed-rank test. To analyze the correlations
between the factors and the outcome, the Spearman’s correlation,
the Kruskal–Wallis test, and the Pearson’s chi-square test were
used. Two-sided P values were reported, and a value of 0.05 was
considered as the level of statistical signiﬁcance. All data were
shown as mean7standard deviation for continuous variables or
frequency (percent) per observation for nominal variables.
Ethics statement
Approval was obtained from the local ethics committee for
an anonymous analysis of routinely collected clinical data,
with a waiver of informed consent.Results
Baseline characteristics of the participants
A total of 20 patients were included in the study. The
duration of the previous RAS blockade therapy was 2.971.9
years, during which the doses were raised in case of 16
patients (80%), and a combination of ACEi and ARB was given
to two patients (10%) for maximizing antiproteinuric effects,
except when disabling hypotension was encountered. All the
patients had been taking 50 mg of sulodexide daily for
11.172.7 months (Table 1).
Pathologic ﬁndings indicated that WHO grade III was
predominant (65%), and the FPE showed over 50% effacement
in most cases (Table 2). There were no signiﬁcant correlations
between the FPE ﬁnding and the initial UPCR or WHO grade.
Changes in blood pressure, biochemical values, and renal
function
Well-maintained blood pressure under 130/80 mmHg was
observed throughout the sulodexide treatment period
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albumin, uric acid, and total cholesterol, were stable without
any signiﬁcant differences between the initial and the ﬁnal
ﬁndings (Table 3). Of the patients, 11 (55%) had chronic
kidney disease (CKD) stage 2, and six (30%) CKD stage 3. No
additional changes in renal function were detected through-
out the treatment period (Table 3).
Antiproteinuric effect of sulodexide
The UPCR during the pre-treatment (baseline) period was
1.570.6 g/g. There were no patients with nephritic-range
proteinuria (43.5 g/g). At the end of the observation period
(11.172.7 months), the UPCR was reduced to 1.170.7 g/g
(P¼0.032) (Fig. 1). While the rate of UPCR reduction was 25%
in more than half of the patients (Fig. 2A), 40% of them who
had a pre-treatment UPCR of more than 1 g/g showed a UPCR
of less than 1 g/g at the ﬁnal observation (Fig. 2B).
The initial ﬁndings were analyzed to identify which of the
following factors were correlated with the decrease in UPCR:
the pre-treatment eGFR, the year-duration of the RAS-block-
ades therapy, the pre-treatment UPCR, and the degree of FPE.
In the analysis, we found that the pre-treatment UPCR
showed a signiﬁcant correlation with the decrease of UPCR
(r¼0.450, P¼0.047), while the other factors did not (Fig. 3).
Adverse effects
No adverse effects were reported after starting the sulo-
dexide administration.Discussion
In this study, we found a possible association between
additional low-dose sulodexide therapy and further antipro-
teinuric effect in patients with IgA nephropathy who had
persistent proteinuria (UPCR 40.5 g/g) despite optimalTable 3. Comparison of laboratory ﬁndings before and after sulodexid
Variables Initial
Serum creatinine (mg/dL) 1.270.3
eGFR (mL/min/1.73 m2) 70.4718.7
Serum albumin (g/dL) 4.170.3
Serum calcium (mg/dL) 9.670.3
Serum phosphate (mg/dL) 3.570.5
Serum uric acid (mg/dL) 6.571.8
Serum total cholesterol (mg/dL) 191.9739.4
eGFR, estimated glomerular ﬁltration rate.
Table 2. Pathologic features of IgA nephropathy at baseline
Features n¼20
WHO classiﬁcation
II 1 (5%)
III 13 (65%)
IV 4 (20%)
V 2 (10%)
Foot process effacement
Mild (o30%) 2 (10%)
Moderate (30–70%) 7 (35%)
Severe (470%) 11 (55%)treatment with RAS blockades. The antiproteinuric effect was
more pronounced in patients with high pre-treatment UPCR.
Sulodexide has been studied as a therapeutic tool for
reducing urinary protein excretion in experimental models of
diabetic nephropathy with diverse physiological properties
related to renoprotection, including prevention of podocyte
apoptosis [16,17], inhibition of heparanase-1 activity [18],
restoration of glomerular glycoprotein in the glomerular base-
ment membrane (GBM) and mesangium with GAG supple-
mentation [19], and restoration of the negative charge of GBM
[20,21]. It also suppresses the overexpression of transforming
growth factor ß (TGF-ß), which is responsible for the enhanced
expression of the mesangial matrix and collagens [22].
The efﬁcacy of sulodexide in patients with diabetic nephro-
pathy has been evaluated in some clinical studies. In the
Diabetic Nephropathy and Albuminuria Sulodexide (Di.N.A.S.)
study [23], the authors reported a decrease of albuminuria,
including macroalbuminuria, by 74% in a dose-dependent man-
ner. Low-dose oral sulodexide, 50 mg daily, was also investi-
gated as an effective therapy for diabetes patients with
albuminuria, including macroalbuminuria, which showed a
reduction of the baseline albuminuria by a geometric mean of
63.7% for 6 months. The effect was greater in the macroalbu-
minuric patients [24]. But a recent randomized controlled study
failed to prove the renoprotective effect of sulodexide in patients
with overt type 2 diabetic nephropathy after 1029 person-years
of follow-up [25]. Disappointing aspects were also seen in the
studies of microalbuminuric diabetic patients. The Sulodexide
Microalbuminuria Trial (SUN-Micro-Trial) could not demon-
strate a decrease of urinary albumin excretion in microalbumi-
nuric patients [26]; the same result was replicated in another
recent randomized controlled trial in which any change ine therapy
Follow-up P
1.270.5 0.437
71.3723.2 0.751
4.270.2 0.330
9.470.5 0.276
3.570.5 0.936
6.670.4 0.360
184.9731.7 0.481
Figure 1. Changes in UPCR before and after sulodexide therapy. The
Wilcoxon signed-rank test was used for the analysis, which indicated
its signiﬁcance (P¼0.032).
UPCR, urinary protein-to-creatinine ratio.
Figure 2. Analyses of the patterns in UPCR reduction by using cumu-
lative histograms. (A) Frequency of each unit in the UPCR changes.
(B) Frequency of each unit in the UPCR decreases at the ﬁnal observation.
UPCR, urinary protein-to-creatinine ratio.
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control group [27].
A report related to GAG therapy in IgA nephropathy came
out a few years ago, which included 12 patients with
progressive IgA nephropathy who were administered RAS
blockades and heparin/warfarin, resulting in the reduction
of 24-hour urinary protein excretion by 71% at the ﬁnal
observation over a mean time period of 34 months [28]. A
randomized, double-blind study of sulodexide treatment in
IgA nephropathy patients was conducted recently [29]. As a
pilot study, 77 patients with IgA nephropathy who already
received RAS blockades participated and were assigned toplacebo, 75 mg of sulodexide daily, or 150 mg daily groups. At
6 months, six (21.4%) of the total 28 patients in the 150 mg
group showed more than 50% reductions of UPCR, while in the
75 mg group only one (4.0%) of the total 24 patients showed
such a reduction. Although our results were similar to theirs
concerning greater-than-half reductions of UPCR, there were
three differences. First, the dose of sulodexide used in our
study was lower than that in their study, but it appeared to be
effective in 25% of the total patients. Second, most of patients
in their study did not have signiﬁcant baseline proteinuria,
the mean being 0.6–0.7 g/g in UPCR, which was much lower
than that in our study (1.570.6 g/g). Unlike in their study, we
failed to see effective proteinuria reduction in patients with
low baseline proteinuria (less than 1 g/g in UPCR) in the
75 mg group. Third, the duration of administration in our
study was twice as long as that in their study. We assume that
with the long-term use of low-dose sulodexide the effect can
be achieved.
Although the presence of persistent proteinuria, over
500 mg/day, has repeatedly been demonstrated to be asso-
ciated with an adverse long-term prognosis, it is very clear
from well-done retrospective studies on large cohorts of
patients with IgA nephropathy that a partial remission of
proteinuria to levels less than 1.0 g/d is associated with a
dramatically better prognosis [6]. In this present study, the
proportion of the patients whose UPCR was decreased to
1.0 g/g was 40%, which is not inferior to the results from
previous studies with glucocorticoid-based therapy. Our
patients were not responsive to RAS blockades, which means
that the result of the study might indicate an additive effect of
sulodexide to the RAS blockade-based therapy cohort in
which the proportion of remission of proteinuria was about
30–40% [7,8]. The estimated response rate of conservative
treatment with RAS blockades or with a RAS blockade–
sulodexide combination therapy could approach about 60–
65%, which is comparable to those (about 70–75%) in gluco-
corticoid-based studies [30,31].
Patients with IgA nephropathy who received little beneﬁts
form RAS blockades have been studied in some trials in an
add-on fashion. Combination of corticosteroids with ACEi or
ARB may provide these patients with a high remission rate of
up to 80% and a stable renal function [32–34]. Addition of oral
calcitriol to RAS blockades for managing persistently protei-
nuric patients resulted in a modest decrease of proteinuria
[35,36].
In this study, throughout the sulodexide treatment period,
no adverse effects were observed. Other trials with sulodexide
did not document serious adverse effects either [26,29]. In a
recent meta-analysis of glucocorticoid-based therapy, how-
ever, the authors reported that widely recognized adverse
effects could occur [31]. A study using a regimen of predni-
solone (40–60 mg daily) for 4 months also reported that
complications related to glucocorticoids occurred in 40% of
patients [37].
Some practical recommendations suggest that the treat-
ment of patients with IgA nephropathy who present hema-
turia and non-nephrotic proteinuria with or without mild
renal impairment should include initial RAS blockades with or
without ﬁsh oil for at least 3–6 months [7,8]. However, the
effects of ﬁsh oil in IgA nephropathy patients were noted to be
inconsistent across studies, and its required doses were
too large for the patients to continue the treatment [8,9].
Therefore, in such cases, we suggest replacing ﬁsh oil with
Figure 3. Correlation analyses between baseline factors and UPCR decreases. Pretreatment eGFR (A), year-duration of RAS blockades therapy
(B), pre-treatment UPCR (C), foot process effacement (D) were the baseline factors used for analyses. The Spearman’s correlation and the Kruskal–
Wallis test were also used in these analyses. Pretreatment UPCR showed a signiﬁcant correlation with decreases of UPCR (P¼0.047).
eGFR, estimated glomerular ﬁltration rate; RAS, renin–angiotensin system; UPCR, urinary protein-to-creatinine ratio.
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RAS blockade–sulodexide combination therapy for up to at
least 12 months in order to achieve an equivalent antiprotei-
nuric effect of glucocorticoid-based therapy, unless there is an
emerging nephrotic proteinuria or serious renal impairment.
Our study has some limitations. Small sample size could
not allow the study to have a strong statistical power, and
even some of the patients (25%) showed increasing UPCR at
the ﬁnal observation. Retrospectively collected data could
not guarantee quality. There was no document of factorsinﬂuencing the values of the variables, such as amounts of
dietary sodium and protein intake and speciﬁc times of urine
collection; neither could we ensure a treatment free of any
adverse effects.
Our study is a case series dealing with uncontrolled paired
comparisons. Therefore, we needed to take historical controls
that contain outcomes such as 24-hour urinary protein excre-
tion or UPCR. We found two trials depicting the progression of
proteinuria using RAS blockades. One of the two trials showed
that proteinuria had decreased by the ﬁrst year in the most
BY Yang et al / Low-dose sulodexide and IgA nephropathy168responsive patients, but did not report the remission rate [38].
Another documented that partial remission rate (o500 mg/d/
1.73 m2) was 40% at the mean 38-month follow-up, but did not
report serial data [39]. Thus, none of them could be used as a
feasible control. From the two trial results, however, we
presumed that about 60% of the patients treated only with
RAS blockades would remain nonresponsive after the ﬁrst year.
The main issue is what to do with these patients [7]. Although
sulodexide recently failed to demonstrate a renoprotective effect
in patients with overt type 2 diabetic nephropathy [25], it is
difﬁcult for us to discard the possibility of sulodexide to treat
IgA nephropathy, the most common nondiabetic glomerular
disease. Large randomized controlled trials with longer mana-
ging periods are needed to conﬁrm its antiproteinuric effect.
In conclusion, our work have shown that low-dose sulo-
dexide has an additional modest antiproteinuric effect on IgA
nephropathy patients receiving RAS blockade therapy.Conﬂict of interest
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